✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Alvocidib is an investigational drug.
There have been 64 clinical trials for Alvocidib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 1999.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Sumitomo Dainippon Pharma Oncology, Inc, and Tolero Pharmaceuticals, Inc.
Recent Clinical Trials for Alvocidib
|Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML||M.D. Anderson Cancer Center||Phase 1/Phase 2|
|Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy||Sumitomo Dainippon Pharma Oncology, Inc||Phase 2|